Edwards Lifesciences (EW) PT Raised to $110 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Edwards Lifesciences (EW) PT Raised to $105 at Piper Sandler
April 21, 2021 9:22 AM EDTPiper Sandler analyst Adam Maeder raised the price target on Edwards Lifesciences (NYSE: EW) to $105.00 (from $97.00) while maintaining a Overweight rating.
... MoreEdwards Lifesciences (EW) PT Raised to $103 at Canaccord Genuity
April 21, 2021 8:26 AM EDTCanaccord Genuity analyst Jason Mills raised the price target on Edwards Lifesciences (NYSE: EW) to $103.00 (from $94.00) while maintaining a Buy rating.
The analyst commented, "EW Q1/21 revenue of $1,217M (+7.8% GAAP Y/Y; +5.0% adjusted CC),beat our estimate of $1,176M and consensus of $1,162M. There was positive Y/Y growth from... More
Edwards Lifesciences (EW) PT Raised to $103 at Stifel
April 21, 2021 8:16 AM EDTStifel analyst Rick Wise raised the price target on Edwards Lifesciences (NYSE: EW) to $103.00 (from $100.00) while maintaining a Buy rating.
The analyst commented, "Overall, Edwards better-than-expected 1Q21 results marked a solid start to 2021, and post-release recovery trend/guidance commentary left us feeling... More
Edwards Lifesciences (EW) PT Raised to $93 at Wells Fargo
April 21, 2021 6:23 AM EDTWells Fargo analyst Lawrence Biegelsen raised the price target on Edwards Lifesciences (NYSE: EW) to $93.00 (from $87.00) while maintaining a Equal Weight rating.... More
Edwards Lifesciences (EW) PT Raised to $108 at Morgan Stanley
April 21, 2021 3:57 AM EDTMorgan Stanley analyst Cecilia Furlong raised the price target on Edwards Lifesciences (NYSE: EW) to $108.00 (from $99.00) while maintaining a Overweight rating.... More
After-Hours Stock Movers 04/20: (LRN) (EW) (ISRG) Higher; (NFLX) (ROKU) (FUBO) Lower (more...)
April 20, 2021 5:20 PM EDTToday's After-Hours Movers
Netflix (NASDAQ: NFLX) 10.5% LOWER; reported Q1 EPS of $3.75, $0.78 better than the analyst estimate of $2.97. Revenue for the quarter came in at $7.16 billion versus the consensus estimate of $7.13 billion. Global streaming paid net additions were 3.98 million versus the guidance of 6 million. The company sees Q2 Global... More
Edwards Lifesciences (EW) Tops Q1 EPS by 6c, Revenues Beat; Offers FY21 EPS Outlook
April 20, 2021 4:17 PM EDTEdwards Lifesciences (NYSE: EW) reported Q1 EPS of $0.54, $0.06 better than the analyst estimate of $0.48. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.16 billion.
First Quarter Highlights and 2021 Outlook
Sales grew 8 percent to $1.2 billion; underlying1 sales grew 5 percentTAVR sales grew 7 percent; underlying sales... More
